Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-11-04Clinical Trial Update: Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy [Phase 3]
Phase 3 trial evaluating rolapitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemo…
-
FDA approval · 2015-10-26FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
FDA approved a supplemental application for ondansetron hydrochloride from Onesource Specialty Pharma Limited. This action updates the regul…
-
FDA approval · 2015-10-26FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
FDA approved a supplemental ANDA for ondansetron hydrochloride from Onesource Specialty Pharma Limited under the ANDA.
-
FDA approval · 2015-10-22FDA Approved: ONDANSETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for ondansetron hydrochloride (ondansetron) submitted by Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2015-10-15Clinical Trial Update: Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer [Phase 3]
A Phase 3 trial comparing antiemetic drugs to prevent delayed nausea after chemotherapy in adult cancer patients has completed. The document…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-10-13FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Sandoz Inc)
FDA approved Palonosetron hydrochloride from Sandoz Inc via an Original Application (ANDA) for use in preventing chemotherapy- and postopera…
-
FDA label_change · 2015-10-09FDA Approved: ONDANSETRON — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for ondansetron hydrochloride from Fresenius Kabi USA, LLC (ANDA202253), typically involving labelin…
-
CLINICAL_TRIALS trial_result · 2015-10-08Clinical Trial Update: Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens [NA]
A completed clinical trial evaluated whether ginger (Zingiber officinale) reduces nausea and vomiting in patients receiving cisplatin-based …
-
CLINICAL_TRIALS withdrawal · 2015-10-02Clinical Trial Update: Relief Band as an Adjunct to Antiemetic Therapy in Patients Who Receive Mod to Highly Emetogenic Chemotherapy [NA]
Clinical trial NCT01980160 evaluating Relief Band as an adjunct to antiemetic therapy in patients receiving moderately to highly emetogenic …
-
FDA approval · 2015-09-28FDA Approved: ONDANSETRON — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for ondansetron from Chartwell RX, LLC, authorizing a generic version of the antiemetic.
-
FDA label_change · 2015-09-28FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
FDA approved Cumberland Pharmaceuticals' supplemental application for SANCUSO (granisetron), expanding its label for the prevention of chemo…
-
CLINICAL_TRIALS trial_result · 2015-09-25Clinical Trial Update: Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) [Phase 3]
Phase 3 trial evaluating fosaprepitant dimeglumine for prevention of chemotherapy-induced nausea and vomiting; results completed with posted…
-
FDA approval · 2015-09-01FDA Approved: VARUBI — Original Application (TerSera Therapeutics LLC)
Varubi (rolapitant) received FDA approval as an antiemetic to prevent chemotherapy-induced nausea and vomiting in adults undergoing initial …
-
FDA approval · 2015-08-28FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (aprepitant) filed by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2015-08-25Clinical Trial Update: An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects [Phase 1]
This Phase 1 open-label study assessed how a single IV dose of rolapitant affects the pharmacokinetics of digoxin, sulfasalazine, and the Co…
-
CLINICAL_TRIALS trial_result · 2015-08-25Clinical Trial Update: An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant [Phase 1]
This update reports the completion of a Phase 1 open-label, randomized bioequivalence study comparing oral and intravenous rolapitant for ch…
-
CLINICAL_TRIALS trial_result · 2015-08-25Clinical Trial Update: A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers [Phase 1]
A Phase 1, two-part single ascending dose study evaluated the safety, tolerability, and pharmacokinetics of intravenous rolapitant in health…
-
CLINICAL_TRIALS trial_result · 2015-07-30Clinical Trial Update: A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) [Phase 4]
Phase 4 clinical trial evaluating aprepitant-based triple regimen for prevention of chemotherapy-induced nausea and vomiting in the first cy…
-
FDA approval · 2015-07-20FDA Approved: APREPITANT — Supplemental Application (Sandoz Inc)
The FDA approved Sandoz Inc's supplemental application for aprepitant, enabling a generic version for prevention of chemotherapy-induced nau…
-
FDA label_change · 2015-07-20FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approves a supplemental application for AKYNZEO (netupitant and palonosetron) to update its labeling for the prevention of chemotherapy-…
-
FDA approval · 2015-07-13FDA Approved: ONDANSETRON — Original Application (Accord Healthcare, Inc.)
FDA approves Accord Healthcare, Inc.'s original application for ondansetron, a generic antiemetic, for prevention of nausea and vomiting due…
-
CLINICAL_TRIALS trial_result · 2015-06-23Clinical Trial Update: Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting [NA]
This document provides an update on a clinical trial comparing distal-proximal point association versus local distribution point association…
-
CLINICAL_TRIALS trial_result · 2015-06-03Clinical Trial Update: Fosaprepitant in Patients Receiving Ifosfamide-based Regimen [NA]
A clinical trial evaluated fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in patients with sarcoma receiving ifosf…
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy [Phase 3]
Phase 3 trial evaluated gabapentin for preventing chemotherapy-induced nausea and vomiting in adults with solid tumors; results have been po…
-
FDA approval · 2015-05-13FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for AKYNZEO (netupitant and palonosetron) to update its labeling per Helsinn’s submission.